Scalper1 News
Specialty drugmaker Allergan (AGN) filed an investor presentation denouncing the business model of would-be hostile acquirer Valeant Pharmaceuticals International (VRX) Tuesday, a day before Valeant hosts a conference call where it’s expected to raise its bid. Both stocks slipped in morning trading on the stock market today. Allergan said in its press release that it employed financial consultants and accountants to examine Valeant’s financial Scalper1 News
Scalper1 News